Clinical pharmacology of dopamine-modulating agents in tourette's syndrome

International Review of Neurobiology

Volumn 112, Issue , 2013, Pages 281-349

  Mogwitz, Sabine ^a   Buse, Judith ^a   Ehrlich, Stefan ^a   Roessner, Veit ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Amisulpride; Aripiprazole; Atypical antipsychotics; Benzamides; Clozapine; Dopamine receptor agonist; Dopamine receptor antagonist; Fluphenazine; Haloperidol; Pergolide; Pimozide; Quetiapine; Risperidone; Sulpiride; Tetrabenazine; Tiapride; Typical antipsychotics; Ziprasidone

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZAMIDE DERIVATIVE; CLONAZEPAM; CLONIDINE; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR AFFECTING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLUPHENAZINE; HALOPERIDOL; HISTAMINE H1 RECEPTOR; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PERGOLIDE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; ROPINIROLE; SEROTONIN RECEPTOR; SULPIRIDE; TETRABENAZINE; TIAPRIDE; UNINDEXED DRUG; ZIPRASIDONE;

AGITATION; AGRANULOCYTOSIS; AKATHISIA; AKINESIA; ALLERGIC RASH; AMENORRHEA; ANXIETY; ARTICLE; ASTHENIA; AUTONOMIC DYSFUNCTION; BLURRED VISION; CLINICAL PHARMACOLOGY; COGNITIVE DEFECT; CONFUSION; DECREASED APPETITE; DEPRESSION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; DYSPHORIA; DYSTONIA; ECG ABNORMALITY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EUPHORIA; EXTRAPYRAMIDAL SYMPTOM; EYE DISEASE; FATIGUE; FEAR; FERTILITY; GALACTORRHEA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; GYNECOMASTIA; HALLUCINATION; HEADACHE; HEART ARREST; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPOGLYCEMIA; HYPOTENSION; INCREASED APPETITE; INSOMNIA; LEUKOCYTE COUNT; LIBIDO DISORDER; LOSS OF APPETITE; LOW DRUG DOSE; MENSTRUAL IRREGULARITY; MENSTRUATION DISORDER; METABOLIC DISORDER; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; MYOCARDITIS; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OCULOGYRIC CRISIS; ORGASM DISORDER; ORTHOSTATIC HYPOTENSION; ORTHOSTATIC INTOLERANCE; PARESTHESIA; PARKINSONISM; PATIENT MONITORING; PERSONALITY DISORDER; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; RABBIT SYNDROME; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESTLESSNESS; RETINOPATHY; RHINITIS; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SOCIAL PHOBIA; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SWEATING; SYSTEMATIC REVIEW (TOPIC); TACHYCARDIA; TARDIVE DYSKINESIA; TORSADE DES POINTES; TOURETTISM; TREMOR; VALVULAR HEART DISEASE; VISUAL DISORDER; VOMITING; WEIGHT GAIN; XEROSTOMIA;

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTICS; BENZAMIDES; CLOZAPINE; DOPAMINE RECEPTOR AGONIST; DOPAMINE RECEPTOR ANTAGONIST; FLUPHENAZINE; HALOPERIDOL; PERGOLIDE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TETRABENAZINE; TIAPRIDE; TYPICAL ANTIPSYCHOTICS; ZIPRASIDONE;

ANIMALS; DOPAMINE; DOPAMINE AGENTS; HUMANS; TOURETTE SYNDROME;

EID: 84888406605     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-411546-0.00010-X     Document Type: Chapter

References (298)

1. Alevizos B., Lykouras L., Zervas I.M., Christodoulou G.N. Risperidone-induced obsessive-compulsive symptoms: A series of six cases. Journal of Clinical Psychopharmacology 2002, 22(5):461-467.
2. Allison D.B., Casey D.E. Antipsychotic-induced weight gain: A review of the literature. The Journal of Clinical Psychiatry 2001, 62(Suppl. 7):22-31.
3. Almandil N.B., Wong I.C.K. Review on the current use of antipsychotic drugs in children and adolescents. Archives of Disease in Childhood. Education and Practice Edition 2011, 96(5):192-196. 10.1136/archdischild-2011-300054.
4. Alvir J.M., Lieberman J.A., Safferman A.Z., Schwimmer J.L., Schaaf J.A. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. The New England Journal of Medicine 1993, 329(3):162-167. 10.1056/NEJM199307153290303.
5. Ananth J., Venkatesh R., Burgoyne K., Gadasalli R., Binford R., Gunatilake S. Atypical antipsychotic induced weight gain: Pathophysiology and management. Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists 2004, 16(2):75-85.
6. Anca M.H., Giladi N., Korczyn A.D. Ropinirole in Gilles de la Tourette syndrome. Neurology 2004, 62(9):1626-1627.
7. Arana-Lechuga Y., Sanchez-Escandón O., de Santiago-Treviño N., Castillo-Montoya C., Terán-Pérez G., Velázquez-Moctezuma J. Risperidone treatment of sleep disturbances in Tourette's syndrome. The Journal of Neuropsychiatry and Clinical Neurosciences 2008, 20(3):375-376. 10.1176/appi.neuropsych.20.3.375.
8. Aravagiri M., Marder S.R., Nuechterlein K.H., Gitlin M.J. Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Therapeutic Drug Monitoring 2003, 25(6):657-664.
9. Atkin K., Kendall F., Gould D., Freeman H., Liberman J., O'Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. The British Journal of Psychiatry: The Journal of Mental Science 1996, 169(4):483-488.
10. Baldessarini R.J. Drugs and treatment of psychiatric disorders: Psychosis and anxiety. The pharmacological basis of therapeutics 1996, 399-430. McGraw-Hill, New York. 9th ed. L.S. Goodman, A. Gilman (Eds.).
11. Baptista T., Molina M.G., Martinez J.L., de Quijada M., Calanche de Cuesta I., Acosta A., et al. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy premenopausal women: Relationship with body weight regulation. Pharmacopsychiatry 1997, 30(6):256-262. 10.1055/s-2007-979503.
12. Barak Y. No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. The Journal of Clinical Psychiatry 2002, 63(2):117-119.
13. Bastiampillai T., Dhillon R., Mohindra R. Exacerbation of tics secondary to clozapine therapy. The Australian and New Zealand Journal of Psychiatry 2008, 42(12):1068-1070.
14. Baumann P., Hiemke C., Ulrich S., Eckermann G., Gaertner I., Gerlach M., et al. The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004, 37(6):243-265. 10.1055/s-2004-832687.
15. Baving L., Schmidt M.H. Obsessive-compulsive disorder, frontostriatal system and the effect of the serotonergic system. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie 2000, 28(1):35-44.
16. Beedham C., Miceli J.J., Obach R.S. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. Journal of Clinical Psychopharmacology 2003, 23(3):229-232. 10.1097/01.jcp.0000084028.22282.f2.
17. Begum M. Clozapine-induced stuttering, facial tics and myoclonic seizures: A case report. The Australian and New Zealand Journal of Psychiatry 2005, 39(3):202. 10.1111/j.1440-1614.2005.01549.x.
18. Ben Djebara M., Worbe Y., Schüpbach M., Hartmann A. Aripiprazole: A treatment for severe coprolalia in "refractory" Gilles de la Tourette syndrome. Movement Disorders: Official Journal of the Movement Disorder Society 2008, 23(3):438-440. 10.1002/mds.21859.
19. Bengi Semerci Z. Olanzapine in Tourette's disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2000, 39(2):140.
20. Bergemann N., Kopitz J., Kress K.R., Frick A. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology 2004, 14(3):245-250. 10.1016/j.euroneuro.2003.09.001.
21. Berna M., Ackermann B., Ruterbories K., Glass S. Determination of olanzapine in human blood by liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B: Analytical Technologies in the Biomedical and Life Sciences 2002, 767(1):163-168.
22. Bersani G., Bressa G.M., Meco G., Marini S., Pozzi F. Combined serotonin-5-HT2 and dopamine-D2 antagonism in schizophrenia: Clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R 64 766). Human Psychopharmacology: Clinical and Experimental 1990, 5(3):225-231. 10.1002/hup.470050307.
23. Bhadrinath B.R. Olanzapine in Tourette syndrome. The British Journal of Psychiatry: The Journal of Mental Science 1998, 172:366.
24. Blair J., Scahill L., State M., Martin A. Electrocardiographic changes in children and adolescents treated with ziprasidone: A prospective study. Journal of the American Academy of Child and Adolescent Psychiatry 2005, 44(1):73-79. 10.1097/01.chi.0000145372.61239.bb.
25. Bloch M.H., Leckman J.F. Clinical course of Tourette syndrome. Journal of Psychosomatic Research 2009, 67(6):497-501. 10.1016/j.jpsychores.2009.09.002.
26. Bock N., Moll G.H., Wicker M., Pilz J., Rüther E., Banaschewski T., et al. Early administration of tiapride to young rats without long-lasting changes in the development of the dopaminergic system. Pharmacopsychiatry 2004, 37(4):163-167. 10.1055/s-2004-827171.
27. Borison R.L., Ang L., Hamilton W.J., Diamond B.I., Davis J.M. Treatment approaches in Gilles de la Tourette syndrome. Brain Research Bulletin 1983, 11(2):205-208.
28. Borison R.L., Sinha D., Haverstock S., McLarnon M.C., Diamond B.I. Efficacy and safety of tiospirone vs. haloperidol and thioridazine in a double-blind, placebo-controlled trial. Psychopharmacology Bulletin 1989, 25(2):190-193.
29. Bressan R.A., Jones H.M., Pilowsky L.S. Atypical antipsychotic drugs and tardive dyskinesia: Relevance of D2 receptor affinity. Journal of Psychopharmacology (Oxford, England) 2004, 18(1):124-127. 10.1177/0269881104040251.
30. Bressolle F., Bres J., Blanchin M.D., Gomeni R. Sulpiride pharmacokinetics in humans after intramuscular administration at three dose levels. Journal of Pharmaceutical Sciences 1984, 73(8):1128-1136.
31. Bruggeman R., van der Linden C., Buitelaar J.K., Gericke G.S., Hawkridge S.M., Temlett J.A. Risperidone versus pimozide in Tourette's disorder: A comparative double-blind parallel-group study. The Journal of Clinical Psychiatry 2001, 62(1):50-56.
32. Bruun R.D. Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder. The American Journal of Psychiatry 1988, 145(5):621-624.
33. Bruun R.D., Budman C.L. Risperidone as a treatment for Tourette's syndrome. The Journal of Clinical Psychiatry 1996, 57(1):29-31.
34. Bubl E., Perlov E., Tebartz Van Elst L. Aripiprazole in patients with Tourette syndrome. The World Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry 2006, 7(2):123-125. 10.1080/15622970500474770.
35. Budman C., Coffey B.J., Shechter R., Schrock M., Wieland N., Spirgel A., et al. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. Journal of Child and Adolescent Psychopharmacology 2008, 18(5):509-515. 10.1089/cap.2007.061.
36. Budman C.L., Gayer A., Lesser M., Shi Q., Bruun R.D. An open-label study of the treatment efficacy of olanzapine for Tourette's disorder. The Journal of Clinical Psychiatry 2001, 62(4):290-294.
37. Buse J., Schoenefeld K., Münchau A., Roessner V. Neuromodulation in Tourette syndrome: Dopamine and beyond. Neuroscience and Biobehavioral Reviews 2013, 37:1069-1084. 10.1016/j.neubiorev.2012.10.004.
38. Byerly M.J., DeVane C.L. Pharmacokinetics of clozapine and risperidone: A review of recent literature. Journal of Clinical Psychopharmacology 1996, 16(2):177-187.
39. Caine E.D., Polinsky R.J., Kartzinel R., Ebert M.H. The trial use of clozapine for abnormal involuntary movement disorders. The American Journal of Psychiatry 1979, 136(3):317-320.
40. Calarge C.A., Nicol G., Xie D., Zimmerman B. Correlates of weight gain during long-term risperidone treatment in children and adolescents. Child and Adolescent Psychiatry and Mental Health 2012, 6(1):21. 10.1186/1753-2000-6-21.
41. Callaghan J.T., Bergstrom R.F., Ptak L.R., Beasley C.M. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clinical Pharmacokinetics 1999, 37(3):177-193.
42. Cath D.C., Hedderly T., Ludolph A.G., Stern J.S., Murphy T., Hartmann A., et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part I: Assessment. European Child & Adolescent Psychiatry 2011, 20(4):155-171. 10.1007/s00787-011-0164-6.
43. Centorrino F., Baldessarini R.J., Kando J.C., Frankenburg F.R., Volpicelli S.A., Flood J.G. Clozapine and metabolites: Concentrations in serum and clinical findings during treatment of chronically psychotic patients. Journal of Clinical Psychopharmacology 1994, 14(2):119-125.
44. Cesková E., Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 1993, 26(4):121-124.
45. Chappel P.B., Leckman J.F., Riddle M.A. The pharmacological treatment of tic disorders. Child & Adolescents Psychiatric Clinics of North America 1995, 4:197-216.
46. Cheng Y.F., Paalzow L.K., Bondesson U., Ekblom B., Eriksson K., Eriksson S.O., et al. Pharmacokinetics of haloperidol in psychotic patients. Psychopharmacology 1987, 91(4):410-414.
47. Chiesa A., Chierzi F., De Ronchi D., Serretti A. Quetiapine for bipolar depression: A systematic review and meta-analysis. International Clinical Psychopharmacology 2012, 27(2):76-90. 10.1097/YIC.0b013e32834e4c56.
48. Choc M.G., Hsuan F., Honigfeld G., Robinson W.T., Ereshefsky L., Crismon M.L., et al. Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharmaceutical Research 1990, 7(4):347-351.
49. Choc M.G., Lehr R.G., Hsuan F., Honigfeld G., Smith H.T., Borison R., et al. Multiple-dose pharmacokinetics of clozapine in patients. Pharmaceutical Research 1987, 4(5):402-405.
50. Chouza C., Romero S., Lorenzo J., Camano J.L., Fontana A.P., Alterwain P., et al. Clinical trial of tiapride in patients with dyskinesia (author's transl). La semaine des hÔpitaux: Organe fondé par l'Association d'enseignement médical des hÔpitaux de Paris 1982, 58(12):725-733.
51. Cianchetti C., Fratta A., Pisano T., Minafra L. Pergolide improvement in neuroleptic-resistant Tourette cases: Various mechanisms causing tics. Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2005, 26(2):137-139. 10.1007/s10072-005-0448-z.
52. Citrome L., Josiassen R., Bark N., Salazar D.E., Mallikaarjun S. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. Journal of Clinical Pharmacology 2005, 45(1):89-93. 10.1177/0091270004269870.
53. Constant E.L., Borras L., Seghers A. Aripiprazole is effective in the treatment of Tourette's disorder. The International Journal of Neuropsychopharmacology/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2006, 9(6):773-774. 10.1017/S1461145706006833.
54. Copur M., Arpaci B., Demir T., Narin H. Clinical effectiveness of quetiapine in children and adolescents with Tourette's syndrome : A retrospective case-note survey. Clinical Drug Investigation 2007, 27(2):123-130.
55. Couchman L., Morgan P.E., Spencer E.P., Flanagan R.J. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: Data from a therapeutic drug monitoring service, 1993-2007. Therapeutic Drug Monitoring 2010, 32(4):438-447. 10.1097/FTD.0b013e3181dad1fb.
56. Csernansky J.G., Mahmoud R., Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. The New England Journal of Medicine 2002, 346(1):16-22. 10.1056/NEJMoa002028.
57. Cui Y., Zheng Y., Yang Y., Liu J., Li J. Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette's disorder: A pilot study in China. Journal of Child and Adolescent Psychopharmacology 2010, 20(4):291-298. 10.1089/cap.2009.0125.
58. Curtis A., Clarke C.E., Rickards H.E. Cannabinoids for Tourette's syndrome. Cochrane Database of Systematic Reviews 2009, (4):1-13. CD006565. 10.1002/14651858.CD006565.pub2.
59. Cutler D., Murphy T., Gilmour J., Heyman I. The quality of life of young people with Tourette syndrome. Child: Care, Health and Development 2009, 35(4):496-504. 10.1111/j.1365-2214.2009.00983.x.
60. Czobor P., Volavka J., Sheitman B., Lindenmayer J.-P., Citrome L., McEvoy J., et al. Antipsychotic-induced weight gain and therapeutic response: A differential association. Journal of Clinical Psychopharmacology 2002, 22(3):244-251.
61. Daniel D.G., Zimbroff D.L., Potkin S.G., Reeves K.R., Harrigan E.P., Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 1999, 20(5):491-505. 10.1016/S0893-133X(98)00090-6.
62. Davies L., Stern J.S., Agrawal N., Robertson M.M. A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole. Human Psychopharmacology 2006, 21(7):447-453. 10.1002/hup.798.
63. De Jonge J.L., Cath D.C., van Balkom A.J.L.M. Quetiapine in patients with Tourette's disorder: An open-label, flexible-dose study. The Journal of Clinical Psychiatry 2007, 68(7):1148-1150.
64. de Lucas Taracena M.T., Montañés Rada F. Olanzapine in Tourette's syndrome: A report of three cases. Actas Españolas de Psiquiatría 2002, 30(2):129-132.
65. Dehning S., Riedel M., Müller N. Aripiprazole in a patient vulnerable to side effects. The American Journal of Psychiatry 2005, 162(3):625. 10.1176/appi.ajp.162.3.625.
66. DeLeon A., Patel N.C., Crismon M.L. Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clinical Therapeutics 2004, 26(5):649-666.
67. DeVane C.L., Nemeroff C.B. Clinical pharmacokinetics of quetiapine: An atypical antipsychotic. Clinical Pharmacokinetics 2001, 40(7):509-522.
68. Dion Y., Annable L., Sandor P., Chouinard G. Risperidone in the treatment of Tourette syndrome: A double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology 2002, 22(1):31-39.
69. Döpfner M., Roessner V., Baetz K., Rothenberger A. Ticstörungen - leitfaden kinder- und jugendpsychotherapie 2009, (Hrsg.), Hogrefe, Göttingen.
70. Drtílková I., Balaštíková B., Lemanová H. Clonazepam, clonidine, and tiapride in children with tic disorder. Homeostasis in Health and Disease 1996, 47(5):216.
71. Duane D.D. Aripiprazole in childhood and adolescence for Tourette syndrome. Journal of Child Neurology 2006, 21(4):358.
72. Dufour A., Desanti C. Pharmacokinetics and metabolism of amisulpride. Annals of General Psychiatry 1988, 3:298-305.
73. Eddy C.M., Rickards H.E., Cavanna A.E. Treatment strategies for tics in Tourette syndrome. Therapeutic Advances in Neurological Disorders 2011, 4(1):25-45. 10.1177/1756285610390261.
74. Eggers C., Rothenberger A., Berghaus U. Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. European Archives of Psychiatry and Neurological Sciences 1988, 237(4):223-229.
75. Eggers C., Schepker R., Oades R.D. Case report: Exacerbation and provocation of tics by imipramine and sulpiride. 1993 European Child and Adolescent Psychiatry 2008, 2:169-176. Retrieved from. http://duepublico.uni-duisburg-essen.de/servlets/DocumentServlet?id=17547.
76. Ehrlich S., Leopold K., Merle J.V., Theophil I., Haag W., Lautenschlager M., et al. Trajectories of agouti-related protein and leptin levels during antipsychotic-associated weight gain in patients with schizophrenia. Journal of Clinical Psychopharmacology 2012, 32(6):767-772. 10.1097/JCP.0b013e318270e5c5.
77. Feinberg M., Carroll B.J. Effects of dopamine agonists and antagonists in Tourette's disease. Archives of General Psychiatry 1979, 36(9):979-985.
78. Fellows L., Ahmad F., Castle D.J., Dusci L.J., Bulsara M.K., Ilett K.F. Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia. Therapeutic Drug Monitoring 2003, 25(6):682-689.
79. Findling R.L., Kauffman R.E., Sallee F.R., Carson W.H., Nyilas M., Mallikaarjun S., et al. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: An open-label, dose-escalation study. Journal of Clinical Psychopharmacology 2008, 28(4):441-446. 10.1097/JCP.0b013e31817dd520.
80. Fleischhaker C., Heiser P., Hennighausen K., Herpertz-Dahlmann B., Holtkamp K., Mehler-Wex C., et al. Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. Journal of Neural Transmission (Vienna, Austria: 1996) 2008, 115(11):1599-1608. 10.1007/s00702-008-0105-9.
81. Forner-Valero J., Aymerich V.B., Oritz-Lopez A. Comperative study of the effects of tiapride and a placebo on the involuntary movements and manual ability of children with cerebromotor disorders. Neuropsychiatrie de l'Enfance et de l'Adolescence 1986, 34:213-216.
82. Forsman A., Ohman R. Pharmacokinetic studies on haloperidol in man. Current Therapeutic Research, Clinical and Experimental 1976, 20(3):319-336.
83. Fountoulakis K.N., Iacovides A., St Kaprinis G. Successful treatment of Tourette's disorder with amisulpride. The Annals of Pharmacotherapy 2004, 38(5):901. 10.1345/aph.1D497.
84. Fountoulakis K.N., Siamouli M., Kantartzis S., Panagiotidis P., Iacovides A., Kaprinis G.S. Acute dystonia with low-dosage aripiprazole in Tourette's disorder. The Annals of Pharmacotherapy 2006, 40(4):775-777. 10.1345/aph.1G331.
85. Freedman R. Schizophrenia. The New England Journal of Medicine 2003, 349(18):1738-1749. 10.1056/NEJMra035458.
86. Freeman R.D., Fast D.K., Burd L., Kerbeshian J., Robertson M.M., Sandor P. An international perspective on Tourette syndrome: Selected findings from 3,500 individuals in 22 countries. Developmental Medicine and Child Neurology 2000, 42(7):436-447.
87. Froemming J.S., Lam Y.W., Jann M.W., Davis C.M. Pharmacokinetics of haloperidol. Clinical Pharmacokinetics 1989, 17(6):396-423.
88. Gaffney G.R., Perry P.J., Lund B.C., Bever-Stille K.A., Arndt S., Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. Journal of the American Academy of Child and Adolescent Psychiatry 2002, 41(3):330-336. 10.1097/00004583-200203000-00013.
89. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophrenia Bulletin 2010, 36(3):518-544. 10.1093/schbul/sbn107.
90. George M.S., Trimble M.R., Ring H.A., Sallee F.R., Robertson M.M. Obsessions in obsessive-compulsive disorder with and without Gilles de la Tourette's syndrome. The American Journal of Psychiatry 1993, 150(1):93-97.
91. Ghanizadeh A. Systemic review of aripiprazole for the treatment of children and adolescents with tic disorders. Neurosciences (Riyadh, Saudi Arabia) 2012, 17(3):200-204.
92. Giakas W.J. Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder. The American Journal of Psychiatry 1995, 152(7):1097-1098.
93. Gilbert D. Treatment of children and adolescents with tics and Tourette syndrome. Journal of Child Neurology 2006, 21(8):690-700.
94. Gilbert D.L., Batterson J.R., Sethuraman G., Sallee F.R. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. Journal of the American Academy of Child and Adolescent Psychiatry 2004, 43(2):206-214. 10.1097/00004583-200402000-00017.
95. Gilbert D.L., Dure L., Sethuraman G., Raab D., Lane J., Sallee F.R. Tic reduction with pergolide in a randomized controlled trial in children. Neurology 2003, 60(4):606-611.
96. Gilbert D.L., Sethuraman G., Sine L., Peters S., Sallee F.R. Tourette's syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology 2000, 54(6):1310-1315.
97. Glassman A.H., Bigger J.T. Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death. The American Journal of Psychiatry 2001, 158(11):1774-1782.
98. Goetz C.G., Tanner C.M., Klawans H.L. Fluphenazine and multifocal tic disorders. Archives of Neurology 1984, 41(3):271-272.
99. Goff D.C., Posever T., Herz L., Simmons J., Kletti N., Lapierre K., et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychopharmacology 1998, 18(4):296-304.
100. Golden G.S. Tardive dyskinesia in Tourette syndrome. Pediatric Neurology 1985, 1(3):192-194.
101. Goodnick P.J., Rodriguez L., Santana O. Antipsychotics: Impact on prolactin levels. Expert Opinion on Pharmacotherapy 2002, 3(10):1381-1391. 10.1517/14656566.3.10.1381.
102. Halbreich U., Kinon B.J., Gilmore J.A., Kahn L.S. Elevated prolactin levels in patients with schizophrenia: Mechanisms and related adverse effects. Psychoneuroendocrinology 2003, 28(Suppl. 1):53-67.
103. Harris K., Singer H.S. Tic disorders: Neural circuits, neurochemistry, and neuroimmunology. Journal of Child Neurology 2006, 21(8):678-689.
104. Hernandez B.S., Fernandez A.E. Risperidone in the treatment of Tourette Syndrome. Acta Pediátrica Española 2005, 63:14-18.
105. Hiemke C., Baumann P., Bergemann N., Conca A., Dietmaier O., Egberts K., et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011. Pharmacopsychiatry 2011, 44(6):195-235.
106. Ho C.-S., Chen H.-J., Chiu N.-C., Shen E.-Y., Lue H.-C. Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder. Journal of the Formosan Medical Association=Taiwan yi zhi 2009, 108(10):788-793. 10.1016/S0929-6646(09)60406-X.
107. Holley F.O., Magliozzi J.R., Stanski D.R., Lombrozo L., Hollister L.E. Haloperidol kinetics after oral and intravenous doses. Clinical Pharmacology and Therapeutics 1983, 33(4):477-484.
108. Hounie A., De Mathis A., Sampaio A.S., Mercadante M.T. Aripiprazole and Tourette syndrome. Revista Brasileira de Psiquiatria 2004, 26(3):213. S1516-44462004000300015.
109. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: Version III-The final common pathway. Schizophrenia Bulletin 2009, 35(3):549-562. 10.1093/schbul/sbp006.
110. Huang T.-L., Lu C.-Y. Correlations between weight changes and lipid profile changes in schizophrenic patients after antipsychotics therapy. Chang Gung Medical Journal 2007, 30(1):26-32.
111. Huang M.L., Van Peer A., Woestenborghs R., De Coster R., Heykants J., Jansen A.A., et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clinical Pharmacology and Therapeutics 1993, 54(3):257-268.
112. Hwang W.-J. Olanzapine treatment for tics in an adult woman with severe Tourette syndrome. Acta Neurologica Taiwanica 2012, 21(4):165-168.
113. Ikenouchi-Sugita A., Yoshimura R., Hayashi K., Ueda N., Umene-Nakano W., Hori H., et al. A case of late-onset Tourette's disorder successfully treated with aripiprazole: View from blood levels of catecholamine metabolites and brain-derived neurotrophic factor (BDNF). The World Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry 2009, 10(4Pt. 3):977-980. 10.1080/15622970902718147.
114. Imondi A.R., Alam A.S., Brennan J.J., Hagerman L.M. Metabolism of sulpiride in man and rhesus monkeys. Archives Internationales de Pharmacodynamie et de Thérapie 1978, 232(1):79-91.
115. Jaffe E., Trémeau F., Sharif Z., Reider R. Clozapine in tardive Tourette syndrome. Biological Psychiatry 1995, 38(3):196-197. 10.1016/0006-3223(95)00218-6.
116. Jankovic J., Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997, 48(2):358-362.
117. Jankovic J., Glaze D.G., Frost J.D. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome. Neurology 1984, 34(5):688-692.
118. Jankovic J., Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988, 38(3):391-394.
119. Jann M.W., Grimsley S.R., Gray E.C., Chang W.H. Pharmacokinetics and pharmacodynamics of clozapine. Clinical Pharmacokinetics 1993, 24(2):161-176.
120. Janssen P.A., Niemegeers C.J., Awouters F., Schellekens K.H., Megens A.A., Meert T.F. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. The Journal of Pharmacology and Experimental Therapeutics 1988, 244(2):685-693.
121. Janssen P.A., Van De Westeringh C., Jagenau A.H., Demoen P.J., Hermans B.K., Van Daele G.H., et al. Chemistry and pharmacology of CNS depressants related to 4-(4-hydroxy-phenylpiperidino)butyrophenone. I. Synthesis and screening data in mice. Journal of Medicinal and Pharmaceutical Chemistry 1959, 1:281-297.
122. Ji W.D., Li Y., Li N., Guo B.Y. Olanzapine for treatment of Tourette syndrome: A double-blind randomized controlled trial. Chinese Journal of Clinical Rehabilitation 2005, 9:66-68.
123. Jones A. Perspectives in drug discovery: 7. Antipsychotic medication 2010, 54-56. Centraltryckeriet, Linköping, Sweden.
124. Joy C.B., Adams C.E., Lawrie S.M. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2006 Oct 18, (4). CD003082. Review. 10.1002/14651858.CD003082.pub2.
125. Junghanns S., Fuhrmann J.T., Simonis G., Oelwein C., Koch R., Strasser R.H., et al. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: A reader-blinded monocenter echocardiography study. Movement Disorders: Official Journal of the Movement Disorder Society 2007, 22(2):234-238. 10.1002/mds.21225.
126. Kalian M., Lerner V., Goldman M. Atypical variants of tardive dyskinesia, treated by a combination of clozapine with propranolol and clozapine with tetrabenazine. The Journal of Nervous and Mental Disease 1993, 181(10):649-651.
127. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988, 45(9):789-796.
128. Karam-Hage M., Ghaziuddin N. Olanzapine in Tourette's disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2000, 39(2):139. 10.1097/00004583-200002000-00007.
129. Kassahun K., Mattiuz E., Nyhart E., Obermeyer B., Gillespie T., Murphy A., et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metabolism and Disposition: The Biological Fate of Chemicals 1997, 25(1):81-93.
130. Kastrup A., Schlotter W., Plewnia C., Bartels M. Treatment of tics in Tourette syndrome with aripiprazole. Journal of Clinical Psychopharmacology 2005, 25(1):94-96.
131. Kawohl W., Schneider F., Vernaleken I., Neuner I. Aripiprazole in the pharmacotherapy of Gilles de la Tourette syndrome in adult patients. The World Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry 2009, 10(4Pt. 3):827-831. 10.1080/15622970701762544.
132. Kennedy C.J., Hunter C.B., Mejia N.I., Jankovic J. Tetrabenazine in the treatment of Tourette syndrome. Journal of Pediatric Neurology 2007, 5:9-13.
133. Kim B.-N., Lee C.-B., Hwang J.-W., Shin M.-S., Cho S.-C. Effectiveness and safety of risperidone for children and adolescents with chronic tic or Tourette disorders in Korea. Journal of Child and Adolescent Psychopharmacology 2005, 15(2):318-324. 10.1089/cap.2005.15.318.
134. Kirino E. Efficacy and safety of aripiprazole in child and adolescent patients. European Child & Adolescent Psychiatry 2012, 21(7):361-368. 10.1007/s00787-012-0270-0.
135. Klepel H., Gebelt H., Koch R.D., Tzenow H. Treatment of extrapyramidal hyperkineses in childhood with tiapride. Psychiatrie, Neurologie, und Medizinische Psychologie 1988, 40(9):516-522.
136. Komossa K., Depping A.M., Gaudchau A., Kissling W., Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database of Systematic Reviews 2010 Dec 8, (12). CD008121. 10.1002/14651858.CD008121.pub2.
137. Koninklijke Nederlandse Maatschappij ter bevordering van de Farmacie Informatorum Medicamentorum 2011, Wetenschappelijk instituut Nederlandse, Den Haag, Nederland.
138. Kossoff E.H., Singer H.S. Tourette syndrome: Clinical characteristics and current management strategies. Paediatric Drugs 2001, 3(5):355-363.
139. Krishnamoorthy J., King B.H. Open-label olanzapine treatment in five preadolescent children. Journal of Child and Adolescent Psychopharmacology 1998, 8(2):107-113.
140. Kroeze W.K., Hufeisen S.J., Popadak B.A., Renock S.M., Steinberg S., Ernsberger P., et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2003, 28(3):519-526. 10.1038/sj.npp.1300027.
141. Kurlan R., Crespi G., Coffey B., Mueller-Vahl K., Koval S., Wunderlich G., et al. A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome. Movement Disorders 2012, 27(6):775-778. 10.1002/mds.24919.
142. Kurlan R., Goetz C., McDermott M. Treatment of ADHD in children with tics: A randomized controlled trial. Neurology 2002, 58(4):527-536.
143. Lane H.-Y., Guo S.-C., Hwang T.-J., Chen Y.-S., Cheng J.J., Lee Y.-C., et al. Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: A pilot study. Journal of Clinical Psychopharmacology 2002, 22(5):530-532.
144. Leckman J.F. Tourette's syndrome. Lancet 2002, 360(9345):1577-1586. 10.1016/S0140-6736(02)11526-1.
145. Letsas K.P., Sideris A., Kounas S.P., Efremidis M., Korantzopoulos P., Kardaras F. Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine. International Journal of Cardiology 2006, 109(2):273-274. 10.1016/j.ijcard.2005.04.031.
146. Levenson J.L. Neuroleptic malignant syndrome. The American Journal of Psychiatry 1985, 142(10):1137-1145.
147. Leysen J.E., Gommeren W., Eens A., de Chaffoy de Courcelles D., Stoof J.C., Janssen P.A. Biochemical profile of risperidone, a new antipsychotic. Journal of Pharmacology and Experimental Therapeutics 1988, 247(2):661-670.
148. Lim L.K.Y., Shim S.Y.M. Risperidone versus haloperidol in the treatment of children with Tourette's syndrome and chronic motor or vocal tic disorder in Korea. European Neuropsychopharmacology 2006, 16:5527.
149. Lindenmayer J.-P., Czobor P., Volavka J., Citrome L., Sheitman B., McEvoy J.P., et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. The American Journal of Psychiatry 2003, 160(2):290-296.
150. Linet L.S. Tourette syndrome, pimozide, and school phobia: The neuroleptic separation anxiety syndrome. The American Journal of Psychiatry 1985, 142(5):613-615.
151. Lipcsey A. Gilles de la Tourette's disease. La semaine des hÔpitaux: Organe fondé par l'Association d'enseignement médical des hÔpitaux de Paris 1983, 59(10):695-696.
152. Lipinski J.F., Sallee F.R., Jackson C., Sethuraman G. Dopamine agonist treatment of Tourette disorder in children: Results of an open-label trial of pergolide. Movement Disorders: Official Journal of the Movement Disorder Society 1997, 12(3):402-407. 10.1002/mds.870120320.
153. Lombroso P.J., Scahill L., King R.A., Lynch K.A., Chappell P.B., Peterson B.S., et al. Risperidone treatment of children and adolescents with chronic tic disorders: A preliminary report. Journal of the American Academy of Child and Adolescent Psychiatry 1995, 34(9):1147-1152. 10.1097/00004583-199509000-00011.
154. López-Muñoz F., Alamo C. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. Brain Research Bulletin 2009, 79(2):130-141. 10.1016/j.brainresbull.2009.01.005.
155. Lyon G.J., Samar S., Jummani R., Hirsch S., Spirgel A., Goldman R., et al. Aripiprazole in children and adolescents with Tourette's disorder: An open-label safety and tolerability study. Journal of Child and Adolescent Psychopharmacology 2009, 19(6):623-633. 10.1089/cap.2009.0035.
156. Magliozzi J.R., Hollister L.E. Elimination half-life and bioavailability of haloperidol in schizophrenic patients. The Journal of Clinical Psychiatry 1985, 46(1):20-21.
157. Mallikaarjun S., Salazar D.E., Bramer S.L. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. Journal of Clinical Pharmacology 2004, 44(2):179-187. 10.1177/0091270003261901.
158. Mannens G., Huang M.L., Meuldermans W., Hendrickx J., Woestenborghs R., Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metabolism and Disposition: The Biological Fate of Chemicals 1993, 21(6):1134-1141.
159. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. The American Journal of Psychiatry 1994, 151(6):825-835.
160. Margolese H.C., Annable L., Dion Y. Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone. The Journal of Clinical Psychiatry 2002, 63(11):1040-1044.
161. Masi G., Gagliano A., Siracusano R., Berloffa S., Calarese T., Ilardo G., et al. Aripiprazole in children with Tourette's disorder and co-morbid attention-deficit/hyperactivity disorder: A 12-week, open-label, preliminary study. Journal of Child and Adolescent Psychopharmacology 2012, 22(2):120-125. 10.1089/cap.2011.0081.
162. Mathé J.F., Cler J.M., Venisse J.L. Therapeutic use of tiapride in movement disorders. La semaine des hÔpitaux: Organe fondé par l'Association d'enseignement médical des hÔpitaux de Paris 1978, 54(13-16):517-520.
163. Mathews M., Muzina D.J. Atypical antipsychotics: New drugs, new challenges. Cleveland Clinic Journal of Medicine 2007, 74(8):597-606.
164. Mauri M.C., Fiorentini A., Volonteri L.S. Quetiapine in acute psychosis and personality disorders during hospitalization. European Neuropsychopharmacology 2004, 14(S3):283-284.
165. Mauri M.C., Steinhilber C.P.C., Marino R., Invernizzi E., Fiorentini A., Cerveri G., et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. European Psychiatry: The Journal of the Association of European Psychiatrists 2005, 20(1):55-60. 10.1016/j.eurpsy.2004.09.009.
166. Mauri M.C., Volonteri L.S., Colasanti A., Fiorentini A., De Gaspari I.F., Bareggi S.R. Clinical pharmacokinetics of atypical antipsychotics: A critical review of the relationship between plasma concentrations and clinical response. Clinical Pharmacokinetics 2007, 46(5):359-388.
167. McCracken J.T., Suddath R., Chang S., Thakur S., Piacentini J. Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. Journal of Child and Adolescent Psychopharmacology 2008, 18(5):501-508. 10.1089/cap.2007.135.
168. McIntyre R.S., Trakas K., Lin D., Balshaw R., Hwang P., Robinson K., et al. Risk of weight gain associated with antipsychotic treatment: Results from the Canadian National Outcomes Measurement Study in Schizophrenia. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 2003, 48(10):689-694.
169. Meisel A., Winter C., Zschenderlein R., Arnold G. Tourette syndrome: Efficient treatment with ziprasidone and normalization of body weight in a patient with excessive weight gain under tiapride. Movement Disorders: Official Journal of the Movement Disorder Society 2004, 19(8):991-992. 10.1002/mds.20218.
170. Meltzer H.Y., Matsubara S., Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. The Journal of Pharmacology and Experimental Therapeutics 1989, 251(1):238-246.
171. Mesotten F., Suy E., Pietquin M., Burton P., Heylen S., Gelders Y. Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. Psychopharmacology 1989, 99(4):445-449.
172. Meyer J.M. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: Metabolic outcomes after 1 year. The Journal of Clinical Psychiatry 2002, 63(5):425-433.
173. Miceli J.J., Wilner K.D., Hansen R.A., Johnson A.C., Apseloff G., Gerber N. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. British Journal of Clinical Pharmacology 2000, 49(Suppl. 1):5S-13S.
174. Mikkelsen E.J., Detlor J., Cohen D.J. School avoidance and social phobia triggered by haloperidol in patients with Tourette's disorder. The American Journal of Psychiatry 1981, 138(12):1572-1576.
175. Miller D.D., Eudicone J.M., Pikalov A., Kim E. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: A post hoc analysis. The Journal of Clinical Psychiatry 2007, 68(12):1901-1906.
176. Miller C.H., Mohr F., Umbricht D., Woerner M., Fleischhacker W.W., Lieberman J.A. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. The Journal of Clinical Psychiatry 1998, 59(2):69-75.
177. Miranda C.M., Castiglioni T.C. Aripiprazole for the treatment of Tourette syndrome. Experience in 10 patients. Revista Médica de Chile 2007, 135(6):773-776. S0034-98872007000600013.
178. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 2005, 10(1):79-104. 10.1038/sj.mp.4001556.
179. Moleman P. Antipsychotica. Praktische Psychofarmacologie 2009, 189-273. Prelum Uitgevers, Houten, The Netherlands.
180. Möller H.-J. Risperidone: A review. Expert Opinion on Pharmacotherapy 2005, 6(5):803-818. 10.1517/14656566.6.5.803.
181. Moore T.A., Buchanan R.W., Buckley P.F., Chiles J.A., Conley R.R., Crismon M.L., et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. The Journal of Clinical Psychiatry 2007, 68(11):1751-1762.
182. Muench J., Hamer A.M. Adverse effects of antipsychotic medications. American Family Physician 2010, 81(5):617-622.
183. Mukaddes N.M., Abali O. Quetiapine treatment of children and adolescents with Tourette's disorder. Journal of Child and Adolescent Psychopharmacology 2003, 13(3):295-299. 10.1089/104454603322572624.
184. Müller-Vahl K.R. The treatment of Tourette's syndrome: Current opinions. Expert Opinion on Pharmacotherapy 2002, 3(7):899-914. 10.1517/14656566.3.7.899.
185. Müller-Vahl K.R. The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome. Der Nervenarzt 2007, 78(3):264. 266-268, 270-271. 10.1007/s00115-006-2131-x.
186. Müller-Vahl K.R., Krueger D. Does Tourette syndrome prevent tardive dyskinesia?. Movement Disorders: Official Journal of the Movement Disorder Society 2011, 26(13):2442-2443. 10.1002/mds.23894.
187. Murphy T.K., Bengtson M.A., Soto O., Edge P.J., Sajid M.W., Shapira N., et al. Case series on the use of aripiprazole for Tourette syndrome. The International Journal of Neuropsychopharmacology/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2005, 8(3):489-490. 10.1017/S1461145705005365.
188. Murphy T.K., Mutch P.J., Reid J.M., Edge P.J., Storch E.A., Bengtson M., et al. Open label aripiprazole in the treatment of youth with tic disorders. Journal of Child and Adolescent Psychopharmacology 2009, 19(4):441-447. 10.1089/cap.2008.0149.
189. Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. The Journal of Pharmacy and Pharmacology 2006, 58(7):871-885. 10.1211/jpp.58.7.0001.
190. Nozawa M., Ohnuma T., Matsubara Y., Sakai Y., Hatano T., Hanzawa R., et al. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Therapeutic Drug Monitoring 2008, 30(1):35-40. 10.1097/FTD.0b013e31816336fd.
191. Olesen O.V., Poulsen B., Linnet K. Fully automated on-line determination of olanzapine in serum for routine therapeutic drug monitoring. Therapeutic Drug Monitoring 2001, 23(1):51-55.
192. Ondo W.G. Tetrabenazine treatment for stereotypies and tics associated with dementia. The Journal of Neuropsychiatry and Clinical Neurosciences 2012, 24(2):208-214. 10.1176/appi.neuropsych.11030077.
193. Ondo W.G., Jong D., Davis A. Comparison of weight gain in treatments for Tourette syndrome: Tetrabenazine versus neuroleptic drugs. Journal of Child Neurology 2008, 23(4):435-437. 10.1177/0883073807307108.
194. Onofrj M., Paci C., D'Andreamatteo G., Toma L. Olanzapine in severe Gilles de la Tourette syndrome: A 52-week double-blind cross-over study vs. low-dose pimozide. Journal of Neurology 2000, 247(6):443-446.
195. Padala P.R., Qadri S.F., Madaan V. Aripiprazole for the treatment of Tourette's disorder. Primary Care Companion to the Journal of Clinical Psychiatry 2005, 7(6):296-299.
196. Pae C.-U. A review of the safety and tolerability of aripiprazole. Expert Opinion on Drug Safety 2009, 8(3):373-386. 10.1517/14740330902835493.
197. Paleacu D., Giladi N., Moore O., Stern A., Honigman S., Badarny S. Tetrabenazine treatment in movement disorders. Clinical Neuropharmacology 2004, 27(5):230-233.
198. Párraga H.C., Párraga M.I., Woodward R.L., Fenning P.A. Quetiapine treatment of children with Tourette's syndrome: Report of two cases. Journal of Child and Adolescent Psychopharmacology 2001, 11(2):187-191. 10.1089/104454601750284108.
199. Párraga H.C., Woodward R.L. Quetiapine for Tourette's syndrome. Journal of the American Academy of Child and Adolescent Psychiatry 2001, 40(4):389-391. 10.1097/00004583-200104000-00005.
200. Pasquier C., Pouplard F. Reflections on child tics. Apropos of a therapeutic trial. Revue de Neuropsychiatrie Infantile et d'hygiène Mentale de l'enfance 1977, 25(10):645-651.
201. Patteet L., Morrens M., Maudens K.E., Niemegeers P., Sabbe B., Neels H. Therapeutic drug monitoring of common antipsychotics. Therapeutic Drug Monitoring 2012, 34(6):629-651. 10.1097/FTD.0b013e3182708ec5.
202. Perez-Iglesias R., Mata I., Pelayo-Teran J.M., Amado J.A., Garcia-Unzueta M.T., Berja A., et al. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. Schizophrenia Research 2009, 107(2-3):115-121. 10.1016/j.schres.2008.09.028.
203. Perry P.J., Lund B.C., Sanger T., Beasley C. Olanzapine plasma concentrations and clinical response: Acute phase results of the North American Olanzapine Trial. Journal of Clinical Psychopharmacology 2001, 21(1):14-20.
204. Peterson B.S., Cohen D.J. The treatment of Tourette's syndrome: Multimodal, developmental intervention. The Journal of Clinical Psychiatry 1998, 59(Suppl. 1):62-72. discussion 73-74.
205. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. The British Journal of Psychiatry: The Journal of Mental Science 1995, 166(6):712-726. discussion 727-733.
206. Pinder R.M., Brogden R.N., Swayer R., Speight T.M., Spencer R., Avery G.S. Pimozide: A review of its pharmacological properties and therapeutic uses in psychiatry. Drugs 1976, 12(1):1-40.
207. Porta M., Sassi M., Cavallazzi M., Fornari M., Brambilla A., Servello D. Tourette's syndrome and role of tetrabenazine: Review and personal experience. Clinical Drug Investigation 2008, 28(7):443-459.
208. Prakash C., Kamel A., Gummerus J., Wilner K. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metabolism and Disposition: The Biological Fate of Chemicals 1997, 25(7):863-872.
209. Pringsheim T., Doja A., Gorman D., McKinlay D., Day L., Billinghurst L., et al. Canadian guidelines for the evidence-based treatment of tic disorders: Pharmacotherapy. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 2012, 57(3):133-143.
210. Pringsheim T., Lam D., Ching H., Patten S. Metabolic and neurological complications of second-generation antipsychotic use in children: A systematic review and meta-analysis of randomized controlled trials. Drug Safety: An International Journal of Medical Toxicology and Drug Experience 2011, 34(8):651-668. 10.2165/11592020-000000000-00000.
211. Pringsheim T., Marras C. Pimozide for tics in Tourette's syndrome. Cochrane Database of Systematic Reviews (Online) 2009, (2):CD006996. 10.1002/14651858.CD006996.pub2.
212. Pringsheim T., Panagiotopoulos C., Davidson J., Ho J. Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatrics & Child Health 2011, 16(9):581-589.
213. Rajagopal S. Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgraduate Medical Journal 2005, 81(959):545-546. 10.1136/pgmj.2004.031161.
214. Rang H., Dale M.M., Ritter J.M., Moore P.K. Pharmacology 2003, Churchill Livingstone, Edinburgh. 5th ed.
215. Regeur L., Pakkenberg B., Fog R., Pakkenberg H. Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette's syndrome. Journal of Neurology, Neurosurgery, and Psychiatry 1986, 49(7):791-795.
216. Reis M., Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. Journal of Clinical Psychopharmacology 2008, 28(3):279-288. 10.1097/JCP.0b013e318172b8d5.
217. Rettenbacher M.A., Eder-Ischia U., Bader A., Edlinger M., Hofer A., Hummer M., et al. QTc variability in schizophrenia patients treated with antipsychotics and healthy controls. Journal of Clinical Psychopharmacology 2005, 25(3):206-210.
218. Riddle M.A., Hardin M.T., Towbin K.E., Leckman J.F., Cohen D.J. Tardive dyskinesia following haloperidol treatment in Tourette's syndrome. Archives of General Psychiatry 1987, 44(1):98-99.
219. Rizzo R., Gulisano M., Calì P.V., Di Pino A. Mandatory electrocardiographic monitoring in young patients treated with psychoactive drugs. European Child & Adolescent Psychiatry 2013, BAnd 47, Ausgabe 6. 10.1007/s00787-013-0413-y.
220. Robertson M.M. Tourette syndrome, associated conditions and the complexities of treatment. Brain: A Journal of Neurology 2000, 123(Pt. 3):425-462.
221. Robertson M.M., Schnieden V., Lees A.J. Management of Gilles de la Tourette syndrome using sulpiride. Clinical Neuropharmacology 1990, 13(3):229-235.
222. Robertson M.M., Scull D.A., Eapen V., Trimble M.R. Risperidone in the treatment of Tourette syndrome: A retrospective case note study. Journal of Psychopharmacology (Oxford, England) 1996, 10(4):317-320. 10.1177/026988119601000411.
223. Robertson M.M., Stern J.S. Gilles de la Tourette syndrome: Symptomatic treatment based on evidence. European Child & Adolescent Psychiatry 2000, 9(Suppl. 1):I60-I75.
224. Roessner V. Therapie der Tic-Störungen 2012, Verlag Hans Huber, Hogrefe AG, Bern.
225. Roessner V., Plessen K.J., Rothenberger A., Ludolph A.G., Rizzo R., Skov L., et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: Pharmacological treatment. European Child & Adolescent Psychiatry 2011, 20(4):173-196. 10.1007/s00787-011-0163-7.
226. Roessner V., Rothenberger A. Pharmacological treatment of tics. Tourette syndrome 2013, Oxford University Press, New York, in print. D. Martino, J. Leckman (Eds.).
227. Roessner V., Schoenefeld K., Buse J., Bender S., Ehrlich S., Münchau A. Pharmacological treatment of tic disorders and Tourette syndrome. Neuropharmacology 2013, 10.1016/j.neuropharm.2012.05.043.
228. Roessner V., Weber A., Becker A., Beck G., Frieling H., Bleich S. Decreased serum activity of semicarbazide-sensitive amine oxidase (SSAO) in patients treated with second generation antipsychotics: A link to impaired glucose metabolism?. European Journal of Clinical Pharmacology 2007, 63(5):425-429. 10.1007/s00228-007-0272-x.
229. Rohde A., Dorsch V.M., Schaefer C. Treatment with psychopharmaca during pregnancy-Part I: As little as possible but as much as necessary. Fortschritte der Neurologie-Psychiatrie 2012, 80(4):227-240. 10.1055/s-0031-1299314.
230. Rosenzweig P., Canal M., Patat A., Bergougnan L., Zieleniuk I., Bianchetti G. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Human Psychopharmacology 2002, 17(1):1-13. 10.1002/hup.320.
231. Ross M.S., Moldofsky H. A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome. The American Journal of Psychiatry 1978, 135(5):585-587.
232. Rothenberger A. Wenn Kinder Tics entwickeln 1991, Fischer, Stuttgart.
233. Rothenberger A., Banaschewski T., Roessner V. Tic- Störungen. Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter 2007, 319-325. Deutscher Ärzteverlag, Köln. Deutsche Gesellschaft für Kinder- u. Jugendpsychiatrie PuP (Ed.).
234. Rothenberger A., Roessner V. Functional neuroimaging investigations of motor networks in Tourette syndrome. Behavioural Neurology 2013, 27(1):47-55. 10.3233/BEN-120281.
235. Rüther E., Degner D., Munzel U., Brunner E., Lenhard G., Biehl J., et al. Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial. Pharmacopsychiatry 1999, 32(4):127-135. 10.1055/s-2007-979218.
236. Sallee F.R., Gilbert D.L., Vinks A.A., Miceli J.J., Robarge L., Wilner K. Pharmacodynamics of ziprasidone in children and adolescents: Impact on dopamine transmission. Journal of the American Academy of Child and Adolescent Psychiatry 2003, 42(8):902-907. 10.1097/01.CHI.0000046897.27264.46.
237. Sallee F.R., Kurlan R., Goetz C.G., Singer H., Scahill L., Law G., et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study. Journal of the American Academy of Child and Adolescent Psychiatry 2000, 39(3):292-299. 10.1097/00004583-200003000-00010.
238. Sallee F.R., Miceli J.J., Tensfeldt T., Robarge L., Wilner K., Patel N.C. Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 2006, 45(6):720-728. 10.1097/01.chi.0000215347.93902.3e.
239. Sallee F.R., Nesbitt L., Jackson C., Sine L., Sethuraman G. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. The American Journal of Psychiatry 1997, 154(8):1057-1062.
240. Sandor P., Musisi S., Moldofsky H., Lang A. Tourette syndrome: A follow-up study. Journal of Clinical Psychopharmacology 1990, 10(3):197-199.
241. Sandor P., Stephens R.J. Risperidone treatment of aggressive behavior in children with Tourette syndrome. Journal of Clinical Psychopharmacology 2000, 20(6):710-712.
242. Scahill L., Chappell P.B., Kim Y.S., Schultz R.T., Katsovich L., Shepherd E., et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. The American Journal of Psychiatry 2001, 158(7):1067-1074.
243. Scahill L., Erenberg G., Berlin C.M., Budman C., Coffey B.J., Jankovic J., et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx: The Journal of the American Society for Experimental NeuroTherapeutics 2006, 3(2):192-206. 10.1016/j.nurx.2006.01.009.
244. Scahill L., Leckman J.F., Schultz R.T., Katsovich L., Peterson B.S. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003, 60(7):1130-1135.
245. Schulz S.C., Thomson R., Brecher M. The efficacy of quetiapine vs haloperidol and placebo: A meta-analytic study of efficacy. Schizophrenia Research 2003, 62(1-2):1-12.
246. Seeman P. Atypical antipsychotics: Mechanism of action. Canadian Journal of Psychiatry. Revue canadienne de Psychiatrie 2002, 47(1):27-38.
247. Seeman P., Corbett R., Van Tol H.H. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 1997, 16(2):93-110. discussion 111-135. 10.1016/S0893-133X(96)00187-X.
248. Seo W.S., Sung H.-M., Sea H.S., Bai D.S. Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. Journal of Child and Adolescent Psychopharmacology 2008, 18(2):197-205. 10.1089/cap.2007.0064.
249. Shapiro A.K., Shapiro E. Controlled study of pimozide vs. placebo in Tourette's syndrome. Journal of the American Academy of Child Psychiatry 1984, 23(2):161-173.
250. Shapiro E., Shapiro E. Treatment of tic disorders with haloperidol 1998, 267-280.
251. Shapiro E., Shapiro A.K., Fulop G., Hubbard M., Mandeli J., Nordlie J., et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Archives of General Psychiatry 1989, 46(8):722-730.
252. Shulman L.M., Singer C., Weiner W.J. Risperidone in Gilles de la Tourette syndrome. Neurology 1995, 45(7):1419.
253. Silay Y.S., Jankovic J. Emerging drugs in Tourette syndrome. Expert Opinion on Emerging Drugs 2005, 10(2):365-380. 10.1517/14728214.10.2.365.
254. Silay Y., Vuong K., Jankovic J. The efficacy and safety of fluphenazine in patients with Tourette syndrome. Neurology 2004, 62:A506. P06.128.
255. Silva R.R., Magee H.J., Friedhoff A.J. Persistent tardive dyskinesia and other neuroleptic-related dyskinesias in Tourette's disorder. Journal of Child and Adolescent Psychopharmacology 1993, 3(3):137-144. 10.1089/cap.1993.3.137.
256. Singer H.S. Current issues in Tourette syndrome. Movement Disorders: Official Journal of the Movement Disorder Society 2000, 15(6):1051-1063.
257. Singer H.S. Treatment of tics and Tourette syndrome. Current Treatment Options in Neurology 2010, 12(6):539-561. 10.1007/s11940-010-0095-4.
258. Singer H.S. The neurochemistry of Tourette syndrome. Tourette syndrome 2013, Oxford University Press, New York, in print. D. Martino, J. Leckman (Eds.).
259. Singer H.S., Gammon K., Quaskey S. Haloperidol, fluphenazine and clonidine in Tourette syndrome: Controversies in treatment. Pediatric Neuroscience 1985, 12(2):71-74.
260. Sitsen J.M.A., Cohen A.F., Franson K.L. Farmacologie 2009, Elsevier Gezondheidszorg, Maarssen, The Netherlands.
261. Spina E., de Leon J. Metabolic drug interactions with newer antipsychotics: A comparative review. Basic & Clinical Pharmacology & Toxicology 2007, 100(1):4-22. 10.1111/j.1742-7843.2007.00017.x.
262. Srour M., Lespérance P., Richer F., Chouinard S. Psychopharmacology of tic disorders. Journal of the Canadian Academy of Child and Adolescent Psychiatry=Journal de l'Académie canadienne de psychiatrie de l'enfant et de l'adolescent 2008, 17(3):150-159.
263. Stahl S.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: Illustrating their mechanism of action. The Journal of Clinical Psychiatry 2001, 62(12):923-924.
264. Stahl S.M., Shayegan D.K. The psychopharmacology of ziprasidone: Receptor-binding properties and real-world psychiatric practice. The Journal of Clinical Psychiatry 2003, 64(Suppl. 19):6-12.
265. Stamenkovic M., Aschauer H., Kasper S. Risperidone for Tourette's syndrome. Lancet 1994, 344(8936):1577-1578.
266. Stamenkovic M., Schindler S.D., Aschauer H.N., De Zwaan M., Willinger U., Resinger E., et al. Effective open-label treatment of Tourette's disorder with olanzapine. International Clinical Psychopharmacology 2000, 15(1):23-28.
267. Stenstrøm A.D., Sindø I. Aripiprazole for the treatment of Tourette's syndrome. Ugeskrift for Laeger 2008, 170(1):58.
268. Stephens R.J., Bassel C., Sandor P. Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome-A pilot study. Journal of Child and Adolescent Psychopharmacology 2004, 14(2):255-266. 10.1089/1044546041648959.
269. Stimmel G.L., Gutierrez M.A., Lee V. Ziprasidone: An atypical antipsychotic drug for the treatment of schizophrenia. Clinical Therapeutics 2002, 24(1):21-37.
270. Stöllberger C., Huber J.O., Finsterer J. Antipsychotic drugs and QT prolongation. International Clinical Psychopharmacology 2005, 20(5):243-251.
271. Swain J.E., Scahill L., Lombroso P.J., King R.A., Leckman J.F. Tourette syndrome and tic disorders: A decade of progress. Journal of the American Academy of Child and Adolescent Psychiatry 2007, 46(8):947-968. 10.1097/chi.0b013e318068fbcc.
272. Sweetman S.M. The complete drug reference 2007, Pharmaceutical Press, London, UK. 35th ed.
273. Tényi T., Csábi G., Trixler M. Antipsychotics and breast-feeding: A review of the literature. Paediatric Drugs 2000, 2(1):23-28.
274. Travis M.J., Burns T., Dursun S., Fahy T., Frangou S., Gray R., et al. Aripiprazole in schizophrenia: Consensus guidelines. International Journal of Clinical Practice 2005, 59(4):485-495. 10.1111/j.1368-5031.2005.00498.x.
275. Trillet M., Moreau T., Daléry J., de Villard R., Aimard G. Treatment of Gilles de la Tourette's disease with amisulpride. La Presse Medicale 1990 Feb 3, 19(4):175.
276. Van der Linden C., Bruggeman R., van Woerkom T.C. Serotonin-dopamine antagonist and Gilles de la Tourette's syndrome: An open pilot dose-titration study with risperidone. Movement Disorders: Official Journal of the Movement Disorder Society 1994, 9(6):687-688. 10.1002/mds.870090617.
277. Van Noord C., Straus S.M.J., Sturkenboom M.C.J., Hofman A., Aarnoudse A.-J.L., Bagnardi V., et al. Psychotropic drugs associated with corrected QT interval prolongation. Journal of Clinical Psychopharmacology 2009, 29(1):9-15. 10.1097/JCP.0b013e318191c6a8.
278. Velamoor V.R. Neuroleptic malignant syndrome. Recognition, prevention and management. Drug Safety: An International Journal of Medical Toxicology and Drug Experience 1998, 19(1):73-82.
279. Vieta E., Locklear J., Günther O., Ekman M., Miltenburger C., Chatterton M.L., et al. Treatment options for bipolar depression: A systematic review of randomized, controlled trials. Journal of Clinical Psychopharmacology 2010, 30(5):579-590. 10.1097/JCP.0b013e3181f15849.
280. Weiden P., Bruun R. Worsening of Tourette's disorder due to neuroleptic-induced akathisia. The American Journal of Psychiatry 1987, 144(4):504-505.
281. Weisman H., Qureshi I.A., Leckman J.F., Scahill L., Bloch M.H. Systematic review: Pharmacological treatment of tic disorders-efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neuroscience and Biobehavioral Reviews 2013 Jul, 37(6):1162-1171. Epub 2012 Oct 23. 10.1016/j.neubiorev.2012.09.008.
282. Welch R., Chue P. Antipsychotic agents and QT changes. Journal of Psychiatry & Neuroscience 2000, 25(2):154-160.
283. Wetterling T., Müssigbrodt H.E. Weight gain: Side effect of atypical neuroleptics?. Journal of Clinical Psychopharmacology 1999, 19(4):316-321.
284. Wiesel F.A., Alfredsson G., Ehrnebo M., Sedvall G. The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. European Journal of Clinical Pharmacology 1980, 17(5):385-391.
285. Wille S.M.R., Cooreman S.G., Neels H.M., Lambert W.E.E. Relevant issues in the monitoring and the toxicology of antidepressants. Critical Reviews in Clinical Laboratory Sciences 2008, 45(1):25-89. 10.1080/10408360701713112.
286. Willmund G., Lee A.H., Wertenauer F., Laier S.A., Lang U.E. Vocal tics associated with ziprasidone. Journal of Clinical Psychopharmacology 2009, 29(6):611-612. 10.1097/JCP.0b013e3181c06dad.
287. Wilner K.D., Tensfeldt T.G., Baris B., Smolarek T.A., Turncliff R.Z., Colburn W.A., et al. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. British Journal of Clinical Pharmacology 2000, 49(Suppl. 1):15S-20S.
288. Winans E. Aripiprazole. American Journal of Health-System Pharmacy: Official Journal of the American Society of Health-System Pharmacists 2003, 60(23):2437-2445.
289. Winter C., Heinz A., Kupsch A., Ströhle A. Aripiprazole in a case presenting with Tourette syndrome and obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 2008, 28(4):452-454. 10.1097/JCP.0b013e31817d86cc.
290. Wolf D.V., Wagner K.D. Tardive dyskinesia, tardive dystonia, and tardive Tourette's syndrome in children and adolescents. Journal of Child and Adolescent Psychopharmacology 1993, 3:175-198.
291. Yoo H.K., Choi S.-H., Park S., Wang H.-R., Hong J.-P., Kim C.-Y. An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. The Journal of Clinical Psychiatry 2007, 68(7):1088-1093.
292. Yoo H.K., Kim J.Y., Kim C.Y. A pilot study of aripiprazole in children and adolescents with Tourette's disorder. Journal of Child and Adolescent Psychopharmacology 2006, 16(4):505-506. 10.1089/cap.2006.16.505.
293. Young A.H., McElroy S.L., Bauer M., Philips N., Chang W., Olausson B., et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). The Journal of Clinical Psychiatry 2010, 71(2):150-162. 10.4088/JCP.08m04995gre.
294. Yvonneau M., Bezard P. Apropos of a case of Gilles de la Tourette's disease blocked by sulpiride. Psycho-biological study. L'Encéphale 1970, 59(5):439-459.
295. Zareba W., Lin D.A. Antipsychotic drugs and QT interval prolongation. The Psychiatric Quarterly 2003, 74(3):291-306.
296. Zhang Jr G.A.V., Bartlett M.G. Bioanalytical methods for the determination of antipsychotic drugs. Biomedical Chromatography 2008, 22(7):671-687. 10.1002/bmc.997.
297. Zhao H., Zhu Y. Risperidone in the treatment of Tourette syndrome. Mental Health Journal 2003, 17:30.
298. Zheng G., Dwoskin L.P., Crooks P.A. Vesicular monoamine transporter 2: Role as a novel target for drug development. The AAPS Journal 2006, 8(4):E682-E692. 10.1208/aapsj080478.